Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1009766 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1009766 34280244!8321400!34280244     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+Pathog 2021 ; 17 (7): e1009766 Nephropedia Template TP {{tp|p=34280244|t=2021. Early antibody responses associated with survival in COVID19 patients |pdf=|usr=}}{{34280244}} gab.com Text Early antibody responses associated with survival in COVID19 patients JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=34280244 #FOAvip Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient's individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. Twit Text FOAVip Early antibody responses associated with survival in COVID19 patients ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=34280244 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34280244 #FOAvip English Wikipedia <ref>{{Cite pmid|34280244}}</ref> Early antibody responses associated with survival in COVID19 patients #MMPMID34280244 Zhou ZH; Dharmarajan S; Lehtimaki M; Kirshner SL; Kozlowski S PLoS Pathog 2021[Jul]; 17 (7): e1009766 PMID34280244show ga Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient's individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/*blood[MESH] |Antibody Specificity[MESH] |Antigens, Viral/immunology[MESH] |COVID-19/*immunology/*mortality[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/blood[MESH] |Linear Models[MESH] |Male[MESH] |Middle Aged[MESH] |Models, Immunological[MESH] |Pandemics[MESH] |Prognosis[MESH] |SARS-CoV-2/*immunology[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH] |Time Factors[MESH]Early antibody responses associated with survival in COVID19 patients (epmc).pdf DeepDyve Pubget Overpricing